DGCI approved drug trial of phytopharmaceutical, favipiravir

The Drug Controller General of India has approved the clinical trials of phytopharmaceutical and favipiravir for the Council for Scientific and Industrial Research (CSIR).

With this approval, CSIR will begin the clinical trial of two drugs to treat COVID-19 patients. The drug trial will begin soon.

CSIR has already been working with pharmaceutical companies for the solution to control COVID-19.

Favipiravir is a proven anti-influenza drug used in Japan, China, and other countries .

CSIR is also exploring a native herb as a biological medicine or phytopharmaceutical. It is already being tested as medicine for dengue for its efficacy to combat COVID-19. It is a herbal medicine extracted from plants.